Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AstraZeneca (GB:AZN – Research Report), Sartorius (GB:0NIR – Research Report) and Caribou Biosciences (CRBU – Research Report).
AstraZeneca (GB:AZN)
TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca yesterday and set a price target of $86.00. The company’s shares closed last Friday at p12130.00.
According to TipRanks.com, Scala is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AstraZeneca with a p12294.80 average price target, representing a 0.9% upside. In a report issued on May 3, Berenberg Bank also maintained a Buy rating on the stock with a £130.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Sartorius (GB:0NIR)
UBS analyst Matthew Weston maintained a Hold rating on Sartorius yesterday and set a price target of EUR314.00. The company’s shares closed yesterday at EUR273.90.
According to TipRanks.com, Weston is ranked #1578 out of 8864 analysts.
Currently, the analyst consensus on Sartorius is a Moderate Buy with an average price target of EUR330.44.
Caribou Biosciences (CRBU)
Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Caribou Biosciences on May 10 and set a price target of $19.00. The company’s shares closed last Thursday at $3.59, close to its 52-week low of $3.44.
According to TipRanks.com, Goonewardene is a 1-star analyst with an average return of
Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $20.00, which is a 446.4% upside from current levels. In a report issued on May 7, RBC Capital also maintained a Buy rating on the stock with a $19.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GB:AZN:
- AstraZeneca’s Breakthrough in COVID-19 Protection for High-Risk Patients
- AstraZeneca CEO Granted Performance-Based Shares
- AstraZeneca withdraws Covid vaccine worldwide, Independent says
- UK Stocks: AstraZeneca (AZN) to Withdraw COVID Vaccine as Demand Wanes
- AstraZeneca price target raised to 13,000 GBp from 12,000 GBp at Berenberg
